UNLABELLED: The differential diagnosis between inflammatory demyelinating disease and malignant glioma is difficult based only on neuroimaging methods. METHODS: Four patients with inflammatory demyelinating disease who presented with clinical and neuroimaging findings strongly suggestive of malignant glioma were examined. RESULTS: MRI showed a mass lesion with prolonged T1 and T2 values and gadolinium enhancement in all cases. Proton MR spectroscopy and (201)Tl SPECT showed findings supportive of the diagnosis of malignant glioma in all cases. However, surgical biopsy revealed inflammatory demyelinating disease. After the diagnosis, 2 patients were treated by steroid administration and 2 were just observed. The gadolinium enhancement of all lesions decreased and finally disappeared. CONCLUSION: Such cases illustrate the importance of considering a demyelinating lesion in the differential diagnosis of a mass lesion. The difficulties encountered in establishing the correct diagnosis of inflammatory disease are related to the variations in the radiologic appearance, which require exclusion of gliomas or other brain tumors by surgical biopsy before the therapeutic strategy can be selected.
UNLABELLED: The differential diagnosis between inflammatory demyelinating disease and malignant glioma is difficult based only on neuroimaging methods. METHODS: Four patients with inflammatory demyelinating disease who presented with clinical and neuroimaging findings strongly suggestive of malignant glioma were examined. RESULTS: MRI showed a mass lesion with prolonged T1 and T2 values and gadolinium enhancement in all cases. Proton MR spectroscopy and (201)Tl SPECT showed findings supportive of the diagnosis of malignant glioma in all cases. However, surgical biopsy revealed inflammatory demyelinating disease. After the diagnosis, 2 patients were treated by steroid administration and 2 were just observed. The gadolinium enhancement of all lesions decreased and finally disappeared. CONCLUSION: Such cases illustrate the importance of considering a demyelinating lesion in the differential diagnosis of a mass lesion. The difficulties encountered in establishing the correct diagnosis of inflammatory disease are related to the variations in the radiologic appearance, which require exclusion of gliomas or other brain tumors by surgical biopsy before the therapeutic strategy can be selected.
Authors: A Seewann; C Enzinger; M Filippi; F Barkhof; A Rovira; A Gass; D Miller; X Montalban; A Thompson; T Yousry; M Tintore; N de Stefano; J Palace; M Rovaris; C Polman; F Fazekas Journal: J Neurol Date: 2007-11-15 Impact factor: 4.849
Authors: Jörg Mauler; Andrew A Maudsley; Karl-Josef Langen; Omid Nikoubashman; Gabriele Stoffels; Sulaiman Sheriff; Philipp Lohmann; Christian Filss; Norbert Galldiks; Elena Rota Kops; N Jon Shah Journal: J Nucl Med Date: 2017-08-28 Impact factor: 10.057
Authors: Rocco Totaro; C Di Carmine; A Splendiani; S Torlone; L Patriarca; C Carrocci; S Sciamanna; C Marini; A Carolei Journal: Neurol Sci Date: 2016-04-15 Impact factor: 3.307
Authors: Sied Kebir; Laurèl Rauschenbach; Martin Glas; Manuel Weber; Lazaros Lazaridis; Teresa Schmidt; Kathy Keyvani; Niklas Schäfer; Asma Milia; Lale Umutlu; Daniela Pierscianek; Martin Stuschke; Michael Forsting; Ulrich Sure; Christoph Kleinschnitz; Gerald Antoch; Patrick M Colletti; Domenico Rubello; Ken Herrmann; Ulrich Herrlinger; Björn Scheffler; Ralph A Bundschuh Journal: J Neurooncol Date: 2021-01-27 Impact factor: 4.130
Authors: C F Lucchinetti; R H Gavrilova; I Metz; J E Parisi; B W Scheithauer; S Weigand; K Thomsen; J Mandrekar; A Altintas; B J Erickson; F König; C Giannini; H Lassmann; L Linbo; S J Pittock; W Brück Journal: Brain Date: 2008-06-05 Impact factor: 13.501